Clinical Trial: Heart and Vascular

EXPAND TAVR II

Full Name

Evolut EXPAND TAVR II Pivotal Trial

Description

Purpose:

To collect information to observe the safety and effectiveness of transcatheter aortic valve replacement (TAVR) in moderate, symptomatic aortic stenosis and before aortic stenosis becomes severe.

The TAVR valve that will be studied in this trial has been approved as a safe and effective treatment for use in severe, symptomatic aortic stenosis condition only.

Description:

TAVR is a treatment to replace your natural valve with an artificial valve that is made from pig tissue supported by a metal frame. The artificial valve is designed to work just like a healthy natural valve, opening and closing with each heartbeat.  To place TAVR in your heart requires a minimally invasive medical procedure.

 

Eligibility

Inclusion Criteria

Inclusion Criteria-including but may not be limited to:

Age 65 and over with moderate, symptomatic aortic stenosis condition.  Symptoms including but not limited to:

  • shortness of breath at rest or on exertion, fatigue, and angina.

To Participate: Please contact the Network Office of Research and Innovation at 610-402-9543.

For additional information:

ClinicalTrials.gov Identifier: NCT05149755

Doctor(s) Running This Study

Specialties

  • Cardiology

Area of focus i

  • Clinical Cardiology
  • Sports Cardiology

Affiliated with

LVPG Cliniciani

Accepting New Patients